These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

509 related items for PubMed ID: 30782163

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature.
    Ohara N, Kobayashi M, Ohashi K, Ito R, Ikeda Y, Kawaguchi G, Yoneoka Y, Hasegawa G, Takada T.
    J Med Case Rep; 2019 Mar 26; 13(1):88. PubMed ID: 30909965
    [Abstract] [Full Text] [Related]

  • 3. Isolated ACTH deficiency probably induced by autoimmune-related mechanism evoked with nivolumab.
    Kitajima K, Ashida K, Wada N, Suetsugu R, Takeichi Y, Sakamoto S, Uchi H, Matsushima T, Shiratsuchi M, Ohnaka K, Furue M, Nomura M.
    Jpn J Clin Oncol; 2017 May 01; 47(5):463-466. PubMed ID: 28334791
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Isolated adrenocorticotropic hormone deficiency possibly caused by nivolumab in a metastatic melanoma patient.
    Fujimura T, Kambayashi Y, Furudate S, Kakizaki A, Hidaka T, Haga T, Hashimoto A, Morimoto R, Aiba S.
    J Dermatol; 2017 Mar 01; 44(3):e13-e14. PubMed ID: 27440178
    [No Abstract] [Full Text] [Related]

  • 6. Isolated adrenocorticotropic hormone deficiency associated with nivolumab therapy.
    Narahira A, Yanagi T, Cho KY, Nakamura A, Miyoshi H, Hata H, Imafuku K, Kitamura S, Shimizu H.
    J Dermatol; 2017 Apr 01; 44(4):e70. PubMed ID: 27608187
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [A Case of Thyroid Dysfunction and Isolated Adrenocorticotropin Deficiency after Nivolumab Therapy for Malignant Melanoma].
    Nishio K, Okada Y, Kurozumi A, Tanaka Y.
    J UOEH; 2021 Apr 01; 43(1):97-102. PubMed ID: 33678791
    [Abstract] [Full Text] [Related]

  • 10. Thyrotoxicosis and Adrenocortical Hormone Deficiency During Immune-checkpoint Inhibitor Treatment for Malignant Melanoma.
    Ariyasu H, Inaba H, Ota T, Yamaoka H, Furukawa Y, Iwakura H, Doi N, Yamamoto Y, Akamizu T.
    In Vivo; 2018 Apr 01; 32(2):345-351. PubMed ID: 29475919
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Late-onset hypophysitis after discontinuation of nivolumab treatment for advanced skin melanoma: a case report.
    Antoniou S, Bazazo G, Röckl L, Papadakis M, Berg C.
    BMC Endocr Disord; 2021 Sep 20; 21(1):191. PubMed ID: 34544399
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Nivolumab-induced hypothyroidism followed by isolated ACTH deficiency.
    Martins Machado C, Almeida Santos L, Barroso A, Oliveira MJ.
    BMJ Case Rep; 2019 Aug 28; 12(8):. PubMed ID: 31466960
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.